Weiss Multi-Strategy Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27,169	Closed	-$2.48M	–	541
2023 Q2	$2.48M	Buy	27,169 +23,796	+705%	+$2.05M	0.05%	438
2023 Q1	$222K	Buy	+3,373	New	+$195K	0.01%	586
2022 Q4	–	Sell	-5,224	Closed	-$357K	–	584
2022 Q3	$357K	Buy	+5,224	New	+$309K	0.01%	578

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weiss Multi-Strategy Advisers's APLS Position: Q3 2023 in Review

Weiss Multi-Strategy Advisers sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 27,169 shares — an estimated $2.48M sold.

Weiss Multi-Strategy Advisers first reported a position in APLS in Q3 2022 and held it in 3 quarters. The position peaked at $2.48M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

Weiss Multi-Strategy Advisers reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 27,169 Apellis Pharmaceuticals shares in Q3 2023, an estimated $2.48M.
Weiss Multi-Strategy Advisers first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Weiss Multi-Strategy Advisers's Apellis Pharmaceuticals position peaked at $2.48M in Q2 2023.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.